December 1, 2022
On Thursday, November 17, Friends of Cancer Research (Friends) was proud to host our 15th Annual Meeting to address critical issues in the development of new oncology drugs. After our last two Annual Meetings were hosted virtually, we welcomed attendees back safely in-person and virtually. The entire event can be viewed here and a summary…
Learn MoreJuly 28, 2022
On Wednesday, July 20, Friends of Cancer Research (Friends) hosted a meeting entitled “Expediting Drug Development: Use of ctDNA as an Early Endpoint.” Welcoming everyone, Jeff Allen, President & CEO of Friends, provided updates regarding Friends’ ctDNA for Monitoring Treatment Response (ctMoniTR) project , a unique collaboration exploring whether changes in ctDNA levels can indicate clinical…
Learn MoreJune 29, 2022
During the American Society of Clinical Oncology (ASCO) Annual Meeting in June, Friends of Cancer Research (Friends) convened rw-Response Pilot participants to discuss initial findings. This pilot expands on Friends’ previous real-world evidence (RWE) work focused on answering the question: “What real-world endpoints can be evaluated and compared across multiple data sources using a common…
Learn MoreApril 7, 2022
Maximizing Benefit and Improving Tolerability for Patients Through Dose Optimization Virtual Event Questions and Answers Friends of Cancer Research (Friends) continues to be committed to improving clinical trial design and drug development to support patients. In September 2021, Friends hosted an event called Beyond Breakthrough: Optimizing the Breakthrough Therapy Designation that highlighted ongoing…
Learn MoreEric Hua | April 5, 2022
On March 29th, Friends of Cancer Research (Friends) convened a virtual meeting to discuss the use of multi-cancer early detection (MCED) screening tests, a promising technology that may support earlier detection of cancers. Dr. Ellen Sigal, Friends’ chair and founder, opened the meeting by highlighting the potential for MCED screening tests to shift the trajectory…
Learn MoreMax Chan | March 3, 2022
On Tuesday, February 22, 2022, Friends of Cancer Research (Friends) hosted a live virtual event that brought together leading voices from various health sectors to discuss key considerations for developing diagnostics tests for rare populations of patients, including those with rare diseases and rare biomarkers. The meeting covered topics surrounding the findings from a recent…
Learn MoreMax Chan | November 15, 2021
On Wednesday, November 10th, Friends of Cancer Research hosted the second day of its 2021 Annual Meeting as a virtual event focused on improving patient outcomes through dose optimization. The first panel discussed the recent white paper on dose optimization and the second panel was a conversation between regulators at the FDA Oncology Center of…
Learn MoreEric Hua | November 15, 2021
On November 9th, Friends of Cancer Research (Friends) held the first of two virtual sessions for their 2021 Annual Meeting, celebrating Friends’ 25th anniversary. The focus of Day 1 was the use of circulating tumor DNA (ctDNA) as an early endpoint. The session opened with a few words of welcome from Friends President and CEO,…
Learn MoreNovember 3, 2021
Each year, the Friends of Cancer Research (Friends) Annual Meeting addresses critical issues in oncology drug development and features experts proposing unique approaches to overcoming current challenges. On Day 2 of the Friends Annual Meeting 2021, panelists will focus on the pressing need for improved dose-finding studies in oncology drug development and discuss proposals to…
Learn MoreBrittany Avin McKelvey | November 3, 2021
The Friends of Cancer Research (Friends) Annual Meeting provides a venue for multiple stakeholders to discuss pressing issues in oncology drug development, providing potential opportunities to overcome challenges and spur future collaborative work. The session on Day 1 of the Friends Annual Meeting 2021 will focus on building a roadmap for the use of changes…
Learn MoreNovember 3, 2021
August 19, 2021
